Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
Can-Fite BioPharma (NYSE:CANF) had its price target lowered by analysts at D. Boral Capital from $11.00 to $4.00. They now have a "buy" rating on the stock.
Can-Fite Provides Update on Clinical and Financial Status
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference